Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 95 plus docetaxel and prednisone for first-line metastatic hormone-refractory prostate cancer
NL-OMON31063Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) and castration-resistant prostate cancer (CRPC) comparing CNTO 95 + docetaxel + prednisone with Docetaxel + prednisone (2 arms). Primary endpoint: Progression-free survival. Started Apr 2007; status: active, not recruiting.
02
Drugs
intetumumabdocetaxelprednisone
03
Conditions
prostate cancer (PCa)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON31063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31063.